knowledge -WSS

knowledge

author：hotspot 2025-08-08 05:33:00 - browse：54326

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Syphilis numbers in the United States reach record heights

focus

WSS

Investment in vaccine development is lagging, report finds

Change Healthcare can notify patients about the breach, HHS says

Venture capital firm's plans to take over Akron hospital face hurdles

How to increase colonoscopy rates? Looks like an AI can help

Medicare drug price negotiation legal challenge met with skepticism

Merck, Johnson & Johnson CEOs will testify on high drug prices

entertainment

knowledge

focus

Cancer drug shortages should be causing more outrage

Medicare Advantage insurers face 0.2% cut to 2025 payments

Virginia high school admissions case could be legal follow

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Wildfire smoke exposes gaps in outdoor worker protections

Ionis drug prevents swelling attacks due to hereditary angioedema

The high cost of giving birth even with insurance

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Jerome Adams on the need for new antivirals for Covid

Change Healthcare can notify patients about the breach, HHS says

hotspot

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Letters to First Opinion on caregivers, digital health, and more

Reconstructing family trees of blood cells may help predict disease

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO: Palliative care found as helpful given virtually as in person

Wikipedia

focus

focus

Wikipedia